Navigation Links
Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idec's Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
Date:7/22/2014

BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few Tecfidera-treated patients are currently experiencing these side effects, signifying either their transient nature or the effective medical management of such events. In the end, fewer than 15 percent of surveyed neurologists felt that Tecfidera-related side effects were an obstacle to their prescribing of the product.

Other key findings from the ChartTrends: Multiple Sclerosis 2014 (US) report:

  • Anti-JC virus antibody testing: The majority of patients tested for anti-JC virus antibodies were treatment naive or were on a DMT other than Biogen Idec's Tysabri at the time of testing, supporting neurologists' reporting that the main driver of assay testing is related to patients' potential candidacy for Tysabri. However, patients (regardless of serostatus) were more likely to stay on their original DMT than switch to another DMT for up to two years after testing.
  • Market potential of emerging therapies: When neurologists hypothetically chose one of the emerging products profiled to switch the audit patient to, Biogen Idec's Plegridy—the product likely to reach the market first—was most frequently selected. Over half of surveyed neurologists believe that Plegridy is most likely to replace the interferon-beta-1a therapy Biogen Idec's Avonex, however patient-level data suggest that the impact of Plegridy is more likely to be spread across the platform injectable DMTs.

Comments from Decision Resour
'/>"/>

SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
2. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
3. Sinovac to Host Conference Call to Report First Quarter 2012 Unaudited Financial Results
4. Sinovac Reports Unaudited First Quarter 2012 Financial Results
5. SCOLR Pharma Announces Unaudited Net Sales of Nutritional Products
6. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
7. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
8. Sinovac to Host Conference Call to Report Second Quarter 2012 Unaudited Financial Results
9. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2012 Results
10. Sinovac Reports Unaudited Second Quarter 2012 Financial Results
11. Groupe Athena Inc., (OTC: GATA) Reports Audited Financials, Announces Record Revenue & Profits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... AUSTIN, Texas , Oct. 31, 2014 /PRNewswire/ ... 3D holographic visualization technologies announced today a strategic ... industry leader in high-end 3D anatomy and biomedical ... the medical and medical education markets.  Zygote maintains ... anatomy and biomedical models and has pioneered development ...
(Date:10/31/2014)... -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP)( ... the development of oral drug delivery systems, announces ... to discuss the clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes ... Eastern time. Shareholders and other interested ...
(Date:10/31/2014)...  Zacks.com announces the list of stocks featured in the Analyst ... news and events impacting stocks and the financial markets. Stocks recently ... - Free Report ), Celgene (Nasdaq: CELG - ... Free Report ), Market Vectors Biotech ETF (AMEX: BBH ... XBI - Free Report ). Today, ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... May 3, 2012 Cardinal Health today reported a 3 ... and a 6 percent increase in non-GAAP operating earnings to ... in non-GAAP diluted earnings per share (EPS) from continuing operations ... solid quarter of revenue growth for both of our business ...
...  Cara Therapeutics, Inc. and Chong Kun Dang Pharmaceutical Corporation ... a licensing agreement that provides CKD Pharm with the ... drug candidate, CR845, in the Republic of Korea.  Under ... up-front payment, including an equity investment, and is eligible ...
Cached Medicine Technology:Cardinal Health Reports Third-Quarter Results 2Cardinal Health Reports Third-Quarter Results 3Cardinal Health Reports Third-Quarter Results 4Cardinal Health Reports Third-Quarter Results 5Cardinal Health Reports Third-Quarter Results 6Cardinal Health Reports Third-Quarter Results 7Cardinal Health Reports Third-Quarter Results 8Cardinal Health Reports Third-Quarter Results 9Cardinal Health Reports Third-Quarter Results 10Cardinal Health Reports Third-Quarter Results 11Cardinal Health Reports Third-Quarter Results 12Cardinal Health Reports Third-Quarter Results 13Cardinal Health Reports Third-Quarter Results 14Cardinal Health Reports Third-Quarter Results 15Cardinal Health Reports Third-Quarter Results 16Cardinal Health Reports Third-Quarter Results 17Cardinal Health Reports Third-Quarter Results 18Cardinal Health Reports Third-Quarter Results 19Cardinal Health Reports Third-Quarter Results 20Cardinal Health Reports Third-Quarter Results 21Cardinal Health Reports Third-Quarter Results 22Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market 2Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market 3
(Date:10/31/2014)... (PRWEB) October 31, 2014 Urban Hydroponics, ... “Company”) today announced it has signed a Binding Letter ... in the urban cultivation sector - Urban Cultivator Inc. ... Lights”), and W3 Metal Inc. (“W3 Metal” and together ... Companies”). Pursuant to the LOI and an earlier ...
(Date:10/31/2014)... 31, 2014 Triple Board Certified surgeon ... restoration services to transform the appearance of military veteran ... Academy of Facial Plastic and Reconstruction Surgery (AAFPRS) Faces ... restore the facial hair Jones lost during an IED ... pro-bono hair restoration procedure, valued around $16,000, took Dr. ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Med-Care Diabetic ... on the highest principles of patient care and service, ... leading health and wellness website, to provide an online ... diabetes. , The Diabetes Health Center will provide ... for those living with diabetes. Content will feature advice ...
(Date:10/31/2014)... Dennis Thompson HealthDay Reporter ... full-court press involving all public health tactics known to ... current West African epidemic, a new study reports. ... in a hygienic way, immediately isolating new patients, tracing ... protection for health care workers -- can stop the ...
(Date:10/31/2014)... Alan Mozes HealthDay Reporter ... the world of 21st-century medicine, organ transplantation is nothing new. ... by the first liver transplant in 1963 and the first ... managed the transplantation of a patient,s entire face. One ... human eye. But if one team of U.S. scientists has ...
Breaking Medicine News(10 mins):Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 2Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 3Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 4Health News:Urban Hydroponics Inc. Signs Definitive Agreement to Merge with Canadian Hydroponics Companies 5Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 2Health News:Med-Care Diabetic & Medical Supplies, Inc. Partners with Lifescript to Provide Online Diabetes Health Center 3Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 2Health News:4 Steps Could Quell Ebola in West Africa, Researchers Say 3Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3
... people who are unlikely to incur high medical expenses. ... families, finds a study of Massachusetts families from Children,s ... Care and Prevention (DACP). The study appears in the ... The researchers, led by Alison Galbraith, MD, MPH, and ...
... survive severe injuries on battlefields such as those in ... infections of their wounds with multidrug resistant bacteria. The ... Staphylococcus aureus (MRSA), Acinetobacter baumannii , ... coli . , Dr Clinton K. Murray, from Brooke ...
... to create open access to information that will enhance ... ORLANDO, Fla., March 29 /PRNewswire/ -- ... GE Healthcare,s Cardiovascular Ultrasound unit announced a formal affiliation ... an integrated solution aimed at improving workflow for echocardiography ...
... allergen breathed in by a person with asthma triggers a ... events to prompt an allergic reaction, said a consortium of ... in Houston in a report that appears online today in ... activates interleukin 25, a key mediator of the allergic response ...
... Relaxin cuts shortness of breath and trimmed hospital stays, phase ... The hormone relaxin reduces shortness of breath and cardiovascular death ... pressure, according to a phase 2 trial conducted in eight ... a few hours of arriving at a hospital, were randomly ...
... Doctor urges first responders to clean equipment regularly ... News) -- One in three stethoscopes used by ... methicillin-resistant Staphylococcus aureus (MRSA) bacteria, a new study ... and Dentistry of New Jersey swabbed 50 stethoscopes ...
Cached Medicine News:Health News:Low-income families with sick children often enrolled in high-deductible health care plans 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 3Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2
MONOJECT SUPRA/HONE Blood Collection Needles - Thin Wall...
VACUETTE PaediatricMulti-Sample Needle...
... Blood Collection Needles are preominantly used for ... single-use. The colour of the needle protective ... needle gauges. For example, yellow symbolises the ... 21 G (0.80 mm) and black 22 ...
This is adapted to microplate or card....
Medicine Products: